


Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-Dec-2021
 Document Type: USP Monographs
 DocId: GUID-83C9C1B2-2452-4A9A-904D-65439FAADEA6_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M33695_03_01
 DOI Ref: 6bxc9

© 2025 USPC
 Do not distribute

Fluorometholone Acetate



$C_{24}H_{31}FO_5$ 418.51

Pregna-1,4-diene-3,20-dione, 17-(acetyloxy)-9-fluoro-11-hydroxy-6-methyl-, (6 α ,11 β);
 9-Fluoro-11 β ,17-dihydroxy-6 α -methylpregna-1,4-diene-3,20-dione, 17 acetate;
 9-Fluoro-11 β -hydroxy-6 α -methyl-3,20-dioxopregna-1,4-dien-17-yl acetate. CAS RN[®]: 3801-06-7; UNII: 9I50C3I3OK.

Change to read:

DEFINITION

Fluorometholone Acetate contains NLT 98.0% and NMT ▲102.0%▲ (USP 1-Dec-2021) of fluorometholone acetate ($C_{24}H_{31}FO_5$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): 197K ▲or 197A▲ (USP 1-Dec-2021)

Delete the following:

- ▲ B. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Ultraviolet-Visible Spectroscopy](#): 197U

Sample solution: 10 μ g/mL in methanol

Acceptance criteria: Meets the requirements▲ (USP 1-Dec-2021)

Add the following:

- ▲ B. The retention time of the fluorometholone acetate peak of the **Sample solution** corresponds to that of the **Standard solution**, as obtained in the **Assay**.▲ (USP 1-Dec-2021)

ASSAY

Change to read:

- **PROCEDURE**

Mobile phase: [Acetonitrile](#) and [water](#) (40:60)

System suitability stock solution: 1.0 mg/mL of [USP Fluorometholone RS](#) prepared as follows. ▲Accurately weigh and transfer a portion of [USP Fluorometholone RS](#) to a suitable volumetric flask. Add [methanol](#) to 8% of the total volume and dilute with [acetonitrile](#) to volume.▲ (USP 1-Dec-2021)

Standard solution: 1.0 mg/mL of [USP Fluorometholone Acetate RS](#) in [acetonitrile](#)

System suitability solution: 0.03 mg/mL each of [USP Fluorometholone RS](#) and [USP Fluorometholone Acetate RS](#) from **System suitability stock solution** and **Standard solution**, respectively, in [acetonitrile](#)

Sample solution: 1.0 mg/mL of Fluorometholone Acetate in [acetonitrile](#)

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; 5- μ m packing [L1](#)

Flow rate: 1.5 mL/min

Injection volume: 10 μ L

▲Run time: NLT 2.5 times the retention time of the fluorometholone acetate peak▲ (USP 1-Dec-2021)

System suitability**Samples:** Standard solution and System suitability solution▲ [Note—See [Table 1](#) for the relative retention times.] ▲ (USP 1-Dec-2021)**Suitability requirements****Resolution:** NLT 10 between fluorometholone and fluorometholone acetate, System suitability solution

▲ ▲ (USP 1-Dec-2021)

Tailing factor: NMT 2.0 for fluorometholone acetate, ▲ Standard solution ▲ (USP 1-Dec-2021)**Relative standard deviation:** NMT ▲ 0.73%, ▲ (USP 1-Dec-2021) Standard solution**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of fluorometholone acetate ($C_{24}H_{31}FO_5$) in the portion of Fluorometholone Acetate taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

 r_u = peak response of fluorometholone acetate from the Sample solution r_s = peak response of fluorometholone acetate from the Standard solution C_s = concentration of [USP Fluorometholone Acetate RS](#) in the Standard solution (mg/mL) C_u = concentration of Fluorometholone Acetate in the Sample solution (mg/mL)**Acceptance criteria:** 98.0%–▲ 102.0% ▲ (USP 1-Dec-2021) on the dried basis**IMPURITIES****Change to read:**• **ORGANIC IMPURITIES****Mobile phase and Sample solution:** Prepare as directed in the Assay.**System suitability stock solution A:** Prepare as directed for the System suitability stock solution in the Assay.**System suitability stock solution B:** Prepare as directed for the Standard solution in the Assay.**System suitability solution:** 0.03 mg/mL each of [USP Fluorometholone RS](#) and [USP Fluorometholone Acetate RS](#), from System suitability stock solution A and System suitability stock solution B, respectively, in [acetonitrile](#)**▲ Sensitivity solution:** 0.5 µg/mL of [USP Fluorometholone Acetate RS](#) in [acetonitrile](#) ▲ (USP 1-Dec-2021)**Standard solution:** 0.03 mg/mL of [USP Fluorometholone RS](#) from System suitability stock solution A in [acetonitrile](#)

▲ ▲ (USP 1-Dec-2021)

Chromatographic system: Proceed as directed in the Assay except for the *Injection volume*.**Injection volume:** 20 µL**System suitability****Samples:** System suitability solution, ▲ Sensitivity solution, and Standard solution[Note—See [Table 1](#) for the relative retention times.] ▲ (USP 1-Dec-2021)**Suitability requirements****Resolution:** NLT 10 between fluorometholone and fluorometholone acetate, System suitability solution

▲ ▲ (USP 1-Dec-2021)

Relative standard deviation: ▲ NMT 5.0% based on peak height response, Standard solution**Signal-to-noise ratio:** NLT 10, Sensitivity solution ▲ (USP 1-Dec-2021)**Analysis****Samples:** Standard solution and Sample solution

▲ ▲ (USP 1-Dec-2021)

Calculate the percentage of fluorometholone or fluorometholone diacetate in the portion of Fluorometholone Acetate taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times (1/F) \times 100$$

 r_u = peak height response of fluorometholone or fluorometholone diacetate from the Sample solution r_s = peak height response of fluorometholone from the Standard solution C_s = concentration of [USP Fluorometholone RS](#) in the Standard solution (mg/mL) C_u = concentration of Fluorometholone Acetate in the Sample solution (mg/mL)

F = relative response factor (see [Table 1](#))

Calculate the percentage of all other fluorometholone acetate impurities in the portion of Fluorometholone Acetate taken:

$$\text{Result} = (r_u/r_T) \times (1/F) \times 100$$

r_u = peak area response of each impurity (except the fluorometholone and fluorometholone diacetate peaks) from the *Sample solution*

r_T = sum of the peak area responses of all impurity peaks plus the fluorometholone acetate peak from the *Sample solution*

F = relative response factor (see [Table 1](#))

Acceptance criteria: See [Table 1](#). ▲ The reporting threshold is 0.05%. ▲ (USP 1-Dec-2021)

Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Fluorometholone	0.6	1.0 ^a	1.0
▲Epoxymethyldeprodone▲ (USP 1-Dec-2021) ^b	0.89	1.0	0.5
Fluorometholone acetate	1.0	—	—
Fluorometholone diacetate▲ ^c (USP 1-Dec-2021)	1.39	0.45 ^a	1.0
▲Epoxyfluorometholone acetate▲ (USP 1-Dec-2021) ^d	1.58	1.0	0.5
▲Fluorometholone acetate diene▲ (USP 1-Dec-2021) ^e	1.77	1.8	0.3
▲Fluorometholone-9(11)-ene acetate▲ (USP 1-Dec-2021) ^f	1.82	1.0	0.2
Any unspecified impurity	—	1.0	0.1
Total impurities	—	—	1.5

^a Relative to fluorometholone. ▲ All other impurities relative to fluorometholone acetate unless otherwise marked. ▲ (USP 1-Dec-2021)

^b ▲9 β ,11 β -Epoxy-17 α -hydroxy-6 α -methylpregna-1,4-diene-3,20-dione.

^c 9-Fluoro-6 α -methyl-3,20-dioxopregna-1,4-dien-11 β ,17-diyi diacetate. ▲ (USP 1-Dec-2021)

^d ▲9 β ,11 β -Epoxy-6 α -methyl-3,20-dioxapregna-1,4-dien-17-yl acetate. ▲ (USP 1-Dec-2021)

^e ▲6 α -Methyl-3,20-dioxopregna-1,4,7,9(11)-tetraen-17-yl acetate. ▲ (USP 1-Dec-2021)

^f ▲6 α -Methyl-3,20-dioxopregna-1,4,9(11)-trien-17-yl acetate. ▲ (USP 1-Dec-2021)

SPECIFIC TESTS

- [OPTICAL ROTATION \(781S\), Procedures, Specific Rotation](#)

Sample solution: 20 mg/mL, in chloroform

Acceptance criteria: +25.0° to +31.0°

- [LOSS ON DRYING \(731\)](#)

Analysis: Dry under vacuum at 60° for 3 h.

Acceptance criteria: NMT 1.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.

- [USP Reference Standards \(11\)](#)
- [USP Fluorometholone RS](#)
- [USP Fluorometholone Acetate RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FLUOROMETHOLONE ACETATE	Documentary Standards Support	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(2)

Current DocID: [GUID-83C9C1B2-2452-4A9A-904D-65439FAADEA6_3_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M33695_03_01

DOI ref: [6bxc9](#)

OFFICIAL